Clinical evaluation of a machine learning-based early warning system for patient deterioration.


Journal

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
ISSN: 1488-2329
Titre abrégé: CMAJ
Pays: Canada
ID NLM: 9711805

Informations de publication

Date de publication:
15 Sep 2024
Historique:
accepted: 01 08 2024
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 16 9 2024
Statut: epublish

Résumé

The implementation and clinical impact of machine learning-based early warning systems for patient deterioration in hospitals have not been well described. We sought to describe the implementation and evaluation of a multifaceted, real-time, machine learning-based early warning system for patient deterioration used in the general internal medicine (GIM) unit of an academic medical centre. In this nonrandomized, controlled study, we evaluated the association between the implementation of a machine learning-based early warning system and clinical outcomes. We used propensity score-based overlap weighting to compare patients in the GIM unit during the intervention period (Nov. 1, 2020, to June 1, 2022) to those admitted during the pre-intervention period (Nov. 1, 2016, to June 1, 2020). In a difference-indifferences analysis, we compared patients in the GIM unit with those in the cardiology, respirology, and nephrology units who did not receive the intervention. We retrospectively calculated system predictions for each patient in the control cohorts, although alerts were sent to clinicians only during the intervention period for patients in GIM. The primary outcome was non-palliative in-hospital death. The study included 13 649 patient admissions in GIM and 8470 patient admissions in subspecialty units. Non-palliative deaths were significantly lower in the intervention period than the pre-intervention period among patients in GIM (1.6% v. 2.1%; adjusted relative risk [RR] 0.74, 95% confidence interval [CI] 0.55-1.00) but not in the subspecialty cohorts (1.9% v. 2.1%; adjusted RR 0.89, 95% CI 0.63-1.28). Among high-risk patients in GIM for whom the system triggered at least 1 alert, the proportion of non-palliative deaths was 7.1% in the intervention period, compared with 10.3% in the pre-intervention period (adjusted RR 0.69, 95% CI 0.46-1.02), with no meaningful difference in subspecialty cohorts (10.4% v. 10.6%; adjusted RR 0.98, 95% CI 0.60-1.59). In the difference-indifferences analysis, the adjusted relative risk reduction for non-palliative death in GIM was 0.79 (95% CI 0.50-1.24). Implementing a machine learning-based early warning system in the GIM unit was associated with lower risk of non-palliative death than in the pre-intervention period. Machine learning-based early warning systems are promising technologies for improving clinical outcomes.

Sections du résumé

BACKGROUND BACKGROUND
The implementation and clinical impact of machine learning-based early warning systems for patient deterioration in hospitals have not been well described. We sought to describe the implementation and evaluation of a multifaceted, real-time, machine learning-based early warning system for patient deterioration used in the general internal medicine (GIM) unit of an academic medical centre.
METHODS METHODS
In this nonrandomized, controlled study, we evaluated the association between the implementation of a machine learning-based early warning system and clinical outcomes. We used propensity score-based overlap weighting to compare patients in the GIM unit during the intervention period (Nov. 1, 2020, to June 1, 2022) to those admitted during the pre-intervention period (Nov. 1, 2016, to June 1, 2020). In a difference-indifferences analysis, we compared patients in the GIM unit with those in the cardiology, respirology, and nephrology units who did not receive the intervention. We retrospectively calculated system predictions for each patient in the control cohorts, although alerts were sent to clinicians only during the intervention period for patients in GIM. The primary outcome was non-palliative in-hospital death.
RESULTS RESULTS
The study included 13 649 patient admissions in GIM and 8470 patient admissions in subspecialty units. Non-palliative deaths were significantly lower in the intervention period than the pre-intervention period among patients in GIM (1.6% v. 2.1%; adjusted relative risk [RR] 0.74, 95% confidence interval [CI] 0.55-1.00) but not in the subspecialty cohorts (1.9% v. 2.1%; adjusted RR 0.89, 95% CI 0.63-1.28). Among high-risk patients in GIM for whom the system triggered at least 1 alert, the proportion of non-palliative deaths was 7.1% in the intervention period, compared with 10.3% in the pre-intervention period (adjusted RR 0.69, 95% CI 0.46-1.02), with no meaningful difference in subspecialty cohorts (10.4% v. 10.6%; adjusted RR 0.98, 95% CI 0.60-1.59). In the difference-indifferences analysis, the adjusted relative risk reduction for non-palliative death in GIM was 0.79 (95% CI 0.50-1.24).
INTERPRETATION CONCLUSIONS
Implementing a machine learning-based early warning system in the GIM unit was associated with lower risk of non-palliative death than in the pre-intervention period. Machine learning-based early warning systems are promising technologies for improving clinical outcomes.

Identifiants

pubmed: 39284602
pii: 196/30/E1027
doi: 10.1503/cmaj.240132
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

E1027-E1037

Informations de copyright

© 2024 CMA Impact Inc. or its licensors.

Déclaration de conflit d'intérêts

Competing interests:: Amol Verma, Chloe Pou-Prom, Joshua Murray, and Muhammad Mamdani co-invented CHARTwatch, which was acquired by a start-up company, Signal1, and they have the potential to acquire minority interests in the company in the future, as does Sebnem Kuzulugil. Amol Verma received travel support from the Alberta Machine Intelligence Institute and is a parttime employee of Ontario Health, outside of the submitted work.

Auteurs

Amol A Verma (AA)

St. Michael's Hospital (Verma, Colacci, Bell, Ailon, Friedrich, Kuzulugil, Yang, Lee, Pou-Prom, Mamdani), Unity Health Toronto; Department of Medicine (Verma, Colacci, Ailon, Friedrich, Lee, Mamdani), and Institute of Health Policy, Management, and Evaluation (Verma, Stukel, Colacci, Murray, Mamdani), and Department of Laboratory Medicine and Pathobiology (Verma, Mamdani), University of Toronto; ICES Central (Stukel); Leslie Dan Faculty of Pharmacy (Mamdani), University of Toronto, Toronto, Ont. amol.verma@mail.utoronto.ca.

Therese A Stukel (TA)

St. Michael's Hospital (Verma, Colacci, Bell, Ailon, Friedrich, Kuzulugil, Yang, Lee, Pou-Prom, Mamdani), Unity Health Toronto; Department of Medicine (Verma, Colacci, Ailon, Friedrich, Lee, Mamdani), and Institute of Health Policy, Management, and Evaluation (Verma, Stukel, Colacci, Murray, Mamdani), and Department of Laboratory Medicine and Pathobiology (Verma, Mamdani), University of Toronto; ICES Central (Stukel); Leslie Dan Faculty of Pharmacy (Mamdani), University of Toronto, Toronto, Ont.

Michael Colacci (M)

St. Michael's Hospital (Verma, Colacci, Bell, Ailon, Friedrich, Kuzulugil, Yang, Lee, Pou-Prom, Mamdani), Unity Health Toronto; Department of Medicine (Verma, Colacci, Ailon, Friedrich, Lee, Mamdani), and Institute of Health Policy, Management, and Evaluation (Verma, Stukel, Colacci, Murray, Mamdani), and Department of Laboratory Medicine and Pathobiology (Verma, Mamdani), University of Toronto; ICES Central (Stukel); Leslie Dan Faculty of Pharmacy (Mamdani), University of Toronto, Toronto, Ont.

Shirley Bell (S)

St. Michael's Hospital (Verma, Colacci, Bell, Ailon, Friedrich, Kuzulugil, Yang, Lee, Pou-Prom, Mamdani), Unity Health Toronto; Department of Medicine (Verma, Colacci, Ailon, Friedrich, Lee, Mamdani), and Institute of Health Policy, Management, and Evaluation (Verma, Stukel, Colacci, Murray, Mamdani), and Department of Laboratory Medicine and Pathobiology (Verma, Mamdani), University of Toronto; ICES Central (Stukel); Leslie Dan Faculty of Pharmacy (Mamdani), University of Toronto, Toronto, Ont.

Jonathan Ailon (J)

St. Michael's Hospital (Verma, Colacci, Bell, Ailon, Friedrich, Kuzulugil, Yang, Lee, Pou-Prom, Mamdani), Unity Health Toronto; Department of Medicine (Verma, Colacci, Ailon, Friedrich, Lee, Mamdani), and Institute of Health Policy, Management, and Evaluation (Verma, Stukel, Colacci, Murray, Mamdani), and Department of Laboratory Medicine and Pathobiology (Verma, Mamdani), University of Toronto; ICES Central (Stukel); Leslie Dan Faculty of Pharmacy (Mamdani), University of Toronto, Toronto, Ont.

Jan O Friedrich (JO)

St. Michael's Hospital (Verma, Colacci, Bell, Ailon, Friedrich, Kuzulugil, Yang, Lee, Pou-Prom, Mamdani), Unity Health Toronto; Department of Medicine (Verma, Colacci, Ailon, Friedrich, Lee, Mamdani), and Institute of Health Policy, Management, and Evaluation (Verma, Stukel, Colacci, Murray, Mamdani), and Department of Laboratory Medicine and Pathobiology (Verma, Mamdani), University of Toronto; ICES Central (Stukel); Leslie Dan Faculty of Pharmacy (Mamdani), University of Toronto, Toronto, Ont.

Joshua Murray (J)

St. Michael's Hospital (Verma, Colacci, Bell, Ailon, Friedrich, Kuzulugil, Yang, Lee, Pou-Prom, Mamdani), Unity Health Toronto; Department of Medicine (Verma, Colacci, Ailon, Friedrich, Lee, Mamdani), and Institute of Health Policy, Management, and Evaluation (Verma, Stukel, Colacci, Murray, Mamdani), and Department of Laboratory Medicine and Pathobiology (Verma, Mamdani), University of Toronto; ICES Central (Stukel); Leslie Dan Faculty of Pharmacy (Mamdani), University of Toronto, Toronto, Ont.

Sebnem Kuzulugil (S)

St. Michael's Hospital (Verma, Colacci, Bell, Ailon, Friedrich, Kuzulugil, Yang, Lee, Pou-Prom, Mamdani), Unity Health Toronto; Department of Medicine (Verma, Colacci, Ailon, Friedrich, Lee, Mamdani), and Institute of Health Policy, Management, and Evaluation (Verma, Stukel, Colacci, Murray, Mamdani), and Department of Laboratory Medicine and Pathobiology (Verma, Mamdani), University of Toronto; ICES Central (Stukel); Leslie Dan Faculty of Pharmacy (Mamdani), University of Toronto, Toronto, Ont.

Zhen Yang (Z)

St. Michael's Hospital (Verma, Colacci, Bell, Ailon, Friedrich, Kuzulugil, Yang, Lee, Pou-Prom, Mamdani), Unity Health Toronto; Department of Medicine (Verma, Colacci, Ailon, Friedrich, Lee, Mamdani), and Institute of Health Policy, Management, and Evaluation (Verma, Stukel, Colacci, Murray, Mamdani), and Department of Laboratory Medicine and Pathobiology (Verma, Mamdani), University of Toronto; ICES Central (Stukel); Leslie Dan Faculty of Pharmacy (Mamdani), University of Toronto, Toronto, Ont.

Yuna Lee (Y)

St. Michael's Hospital (Verma, Colacci, Bell, Ailon, Friedrich, Kuzulugil, Yang, Lee, Pou-Prom, Mamdani), Unity Health Toronto; Department of Medicine (Verma, Colacci, Ailon, Friedrich, Lee, Mamdani), and Institute of Health Policy, Management, and Evaluation (Verma, Stukel, Colacci, Murray, Mamdani), and Department of Laboratory Medicine and Pathobiology (Verma, Mamdani), University of Toronto; ICES Central (Stukel); Leslie Dan Faculty of Pharmacy (Mamdani), University of Toronto, Toronto, Ont.

Chloe Pou-Prom (C)

St. Michael's Hospital (Verma, Colacci, Bell, Ailon, Friedrich, Kuzulugil, Yang, Lee, Pou-Prom, Mamdani), Unity Health Toronto; Department of Medicine (Verma, Colacci, Ailon, Friedrich, Lee, Mamdani), and Institute of Health Policy, Management, and Evaluation (Verma, Stukel, Colacci, Murray, Mamdani), and Department of Laboratory Medicine and Pathobiology (Verma, Mamdani), University of Toronto; ICES Central (Stukel); Leslie Dan Faculty of Pharmacy (Mamdani), University of Toronto, Toronto, Ont.

Muhammad Mamdani (M)

St. Michael's Hospital (Verma, Colacci, Bell, Ailon, Friedrich, Kuzulugil, Yang, Lee, Pou-Prom, Mamdani), Unity Health Toronto; Department of Medicine (Verma, Colacci, Ailon, Friedrich, Lee, Mamdani), and Institute of Health Policy, Management, and Evaluation (Verma, Stukel, Colacci, Murray, Mamdani), and Department of Laboratory Medicine and Pathobiology (Verma, Mamdani), University of Toronto; ICES Central (Stukel); Leslie Dan Faculty of Pharmacy (Mamdani), University of Toronto, Toronto, Ont.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH